Advertisement


Brian Ball, MD, on Higher-Risk MDS: Bexmarilimab and Azacitidine

ASH 2025

Advertisement

Brian Ball, MD, of City of Hope, presents updated results from the phase I/II BEXMAB study. They showed that the doublet had encouraging activity in patients with TP53-mutant, higher-risk MDS; translational data support the combination regimen’s potential for altering immune dysregulation in this subtype (Abstract 236). 



Related Videos

Myelodysplastic Syndromes

Guillermo Garcia-Manero, MD, on MDS: Research Highlights From ASH 2025

Guillermo Garcia-Manero, MD, of The University of Texas MD Anderson Cancer Center, reviews data from three abstracts in myelodysplastic syndromes (MDS) presented at this year’s meeting: outcomes from the phase III VERONA trial of venetoclax with azacitidine vs placebo with azacitidine in patients with treatment-naive intermediate- and higher-risk MDS (Abstract 235); safety and efficacy results from a phase Ib trial of a dual IRAK1/4 inhibitor in patients with relapsed/refractory lower-risk MDS (Abstract 489); and results from the phase II ASTX030-01 trial, showing pharmacokinetic, efficacy, and safety data of oral ASTX030 in patients with MDS (Abstract 491). 

Multiple Myeloma

Shahzad Raza, MD, on Relapsed/Refractory Multiple Myeloma: Novel Doublet in Patients With Extramedullary Disease

Shahzad Raza, MD, of Cleveland Clinic, presents updated phase II results of the RedirecTT-1 trial, focusing on the efficacy and safety of talquetamab combined with teclistamab in patients with relapsed/refractory multiple myeloma and extramedullary disease (Abstract 698). The study also received simultaneous publication in The New England Journal of Medicine.

Leukemia

Aaron Logan, MD, PhD, on Relapsed/Refractory B-Cell ALL: Real-World Data on Brexucabtagene Autoleucel and Transplant

Aaron Logan, MD, PhD, of UCSF Health, discusses research examining the effect of transplant before or after treatment with brexucabtagene autoleucel in the real world for adult patients with relapsed or refractory Philadelphia chromosome–negative B-cell acute lymphoblastic leukemia (ALL) (Abstract 516). 

Multiple Myeloma

Andrew Portuguese, MD, on Multiple Myeloma: Real-World Outcomes With Elranatamab

Andrew Portuguese, MD, of Fred Hutchinson Cancer Center, discusses findings from a multicenter analysis from the U.S. Multiple Myeloma Immunotherapy Consortium looking at the real-world safety and efficacy of the BCMA-CD3 bispecific antibody elranatamab (Abstract 136).  

Hematologic Malignancies
AI in Oncology

Aaron Gerds, MD, on Using an AI System to Identify Patients Eligible for a Polycythemia Vera Trial

Aaron Gerds, MD, of Cleveland Clinic, reviews results of an evaluation of Synapsis AI, a medically trained, large language model–based end-to-end system, focusing on its accuracy and efficiency in identifying eligible patients for an active phase III polycythemia vera clinical trial (Abstract 4340). 

Advertisement

Advertisement




Advertisement